Full-Time

Senior Associate Scientist

Immunology, VI Next

Confirmed live in the last 24 hours

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

10,001+ employees

Develops biopharmaceuticals for serious diseases

Compensation Overview

$79.1k - $129.1k/yr

Senior

Tarrytown, NY, USA

Category
Lab & Research
Medical Research
Required Skills
Excel/Numbers/Sheets
Requirements
  • MS/BS in immunology, cell biology, molecular biology, or related fields
  • 3+ years of relevant experimental techniques
  • Strong knowledge base of immunology
  • Experience in mouse handling
  • Experience in multi-color flow cytometry
  • Experience in immunological methods
Responsibilities
  • Supporting mouse in vivo studies, including performing injections (IV, IP, SQ), routinely bleeding mice, harvesting tissues and isolating cells for downstream functional assays
  • Performing multicolor (>12 color) flow cytometry and analyze flow cytometry data
  • Performing and analyzing immunoassays such as ELISA and MSD
  • Conducting cell co-culture experiments such as cytotoxicity assays and mixed lymphocyte reaction (MLR)
  • Constructing DNA vectors and viral vectors for in vitro and in vivo studies
  • Culturing and engineering primary cells and cell lines using transfection and viral transduction
  • Maintaining an organized lab notebook, analyzing (FlowJo, Excel, GraphPad Prism, etc.) and presenting data at various internal meetings
Desired Qualifications
  • Experience in the research of targeted therapeutics including antibodies and cell therapies
  • Experience in development of complex mouse models of tumors and transplantation
  • Ability to design experiments, analyze, and troubleshoot independently
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops medicines aimed at treating serious diseases such as cancer, eye diseases, and allergic conditions. The company uses its own technologies and extensive research to create new therapies, often working with academic institutions and other pharmaceutical companies to enhance its efforts. Regeneron stands out from competitors by focusing on strategic partnerships that allow for shared development costs and profits, which helps bring new treatments to market more effectively. The goal of Regeneron is to improve patient outcomes through the development of life-changing medicines.

Company Size

10,001+

Company Stage

IPO

Headquarters

Town of Greenburgh, New York

Founded

1988

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of 23andMe assets boosts Regeneron's consumer genomics and drug discovery.
  • Collaboration with Sanofi and Viz.ai enhances AI solutions for COPD management.
  • AIM4 trial launch with Sanofi reflects commitment to precision medicine.

What critics are saying

  • 23andMe acquisition may face regulatory scrutiny, delaying strategic benefits.
  • AERIFY-2 study failure could impact investor confidence in COPD projects.
  • 23andMe acquisition raises privacy concerns, affecting consumer trust.

What makes Regeneron Pharmaceuticals unique

  • Regeneron excels in leveraging proprietary technologies for drug discovery and development.
  • The company has strong collaborations with academic and research institutions.
  • Regeneron's strategic partnerships enhance its R&D capabilities and market reach.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Wellness Program

Paid Vacation

Equity Awards

Annual Bonuses

Flexible Work Hours

Company News

PharmiWeb
Jun 2nd, 2025
Itepekimab Met The Primary Endpoint In One Of Two Copd Phase 3 Studies

Itepekimab met the primary endpoint in one of two COPD phase 3 studies. AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically meaningful benefit. AERIFY-2 study, a second Phase 3 study, did not meet the primary endpoint despite a benefit seen earlier in the study

MarketBeat
Jun 1st, 2025
Summit Global Investments Invests $849,000 in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Regeneron Pharmaceuticals Inc. purchased a new stake in Alnylam Pharmaceuticals in the 4th quarter worth approximately $1,045,822,000.

CNBC
May 27th, 2025
23Andme To Delist From Nasdaq, Deregister With Sec

A sign is posted in front of the 23andMe headquarters in Sunnyvale, California, on Feb. 1, 2024.Justin Sullivan | Getty Images23andMe on Tuesday announced it will voluntarily delist from the Nasdaq and de-register with the U.S. Securities and Exchange Commission, according to a release. The move comes after Regeneron Pharmaceuticals said earlier this month that it will acquire "substantially all" of 23andMe's assets for $256 million. The drugmaker came out on top following a bankruptcy auction for 23andMe, a once high-flying genetic testing company that filed for for Chapter 11 bankruptcy protection in March.This is breaking news. Please refresh for updates

Pharmaceutical Technology
May 20th, 2025
ATS 2025: Sanofi and Regeneron to launch new AIM4 trial for personalised asthma care

At the American Thoracic Society (ATS) 2025 Congress on 19 May, Sanofi and Regeneron announced the launch of a new Phase IIIb/IV clinical trial, AIM4, during an evening industry symposium.

Regeneron Pharmaceuticals
May 20th, 2025
Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness | Regeneron Pharmaceuticals Inc.

Purchase is subject to bankruptcy court and regulatory approvals Regeneron will prioritize the privacy, security and ethical use of 23andMe’s customer data; stands ready to work with independent, court-appointed Customer Privacy Ombudsman Planned purchase to strengthen Regeneron’s ongoing